Skip to content
CancerIndex

Publication

Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing.

Karim Obeid, Mark Konijnenberg, Ekaterina Bezverkhniaia, Theodosia Maina, Berthold A Nock, Vladimir Tolmachev, Panagiotis Kanellopoulos, Anna Orlova

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieOct 1, 2026PMID 42700618doi:10.1016/j.biopha.2026.119908 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate and breast cancers and hence serves as a legitimate target for radionuclide therapy (TRT). Radiolabeled GRPR antagonists are attractive radionuclide-carriers for TRT, due to their rapid tissue penetration, fast…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.